oestrogen

CLINICAL USE

Second line haemostatic agent for uraemic bleeding

DOSE IN NORMAL RENAL FUNCTION

0.6 mg/kg/day for 5 days

PHARMACOKINETICS

Molecular weight :–

%Protein binding :–

%Excreted unchanged in urine : –

Volume of distribution (L/kg) :–

half-life – normal/ESRD (hrs) :–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in normal renal function

HD :Unknown dialysability. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Ciclosporin: concentration of ciclosporin increased

Anticoagulants: antagonism of anticoagulant effect of coumarins and phenindione

Anti-epileptics: accelerate metabolism of oestrogens

ADMINISTRATION

Reconstition

To 50 mL with sodium chloride 0.9%

Route

Rate of Administration

Over a minimum of 30 minutes

Comments

–

OTHER INFORMATION

Duration of effect about 14 days Used in association with desmopressin (DDAVP) in intractable casesOrally

10 to 20 : mg daily for 5–7 days Conjugated oestrogens are a mixture of sodium oestrone sulphate and sodium equilin sulphate and other oestrogenic substances of the type excreted by pregnant maresoestrogen, conjugated (unlicensed product).

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home